Summary by Moomoo AI
Novo Nordisk A/S, a leading global healthcare company, has announced the continuation of its share repurchase program, which began on February 6, 2024. The program, compliant with the European Union's Market Abuse Regulation (MAR) and Safe Harbour Rules, is part of a larger DKK 20 billion buyback plan set to occur over a 12-month period. From February 6 to April 30, 2024, the company plans to repurchase B shares worth up to DKK 2.1 billion. As of March 8, 2024, Novo Nordisk has repurchased 1,031,500 B shares at an average price of DKK 845.39 each, totaling DKK 872,024,243. These transactions have increased the company's treasury shares to 47,572,207 B shares, representing 1.1% of the share capital. Novo Nordisk, established in 1923 and headquartered in Denmark, focuses on defeating serious chronic diseases and is known for its significant contributions to diabetes care. The company employs approximately 63,400 people worldwide and markets its products in about 170 countries.